[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100432414":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":55,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":20,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":20,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":20,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Region Stockholm","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HPV-vaccination","EXPERIMENTAL","Women ages 22-26 will be offered concomitant vaccination (1 dose of Gardasil9) and HPV screening. A second dose of Gardasil9 will be administered 3 years later.",[13],"Biological: Gardasil9",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","Gardasil9","Concomitant vaccination and HPV screening. Gardasil9 will be administered using standard dosage. 1 dose at recruitment and the 2nd dose 3 years later.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Joakim Dillner, MD, PhD","Karolinska University Hospital Laboratory","STUDY_DIRECTOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Miriam Elfström, PhD","CONTACT","+46703816277","miriam.elfstrom@sll.se",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":35},"Helena Andersson, PhD","+46768871126","helena.t.andersson@sll.se",[37],{"facility":38,"status":39,"city":40,"state":20,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Cancer prevention, screening, and counseling unit, Regional Cancer Center of Stockholm-Gotland","RECRUITING","Stockholm","10239","Sweden","SE",{"type":45,"coordinates":46},"Point",[47,48],18.06871,59.32938,{"lat":48,"lon":47},[51],{"name":52,"role":29,"phone":53,"phoneExt":20,"email":54},"Malin Vikström, BSN","+46(0)8-123 131 14","malin.vikstrom@sll.se",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Miriam Elfström","Chief development officer",[60],{"name":61,"class":62},"Karolinska University Hospital","OTHER","100432414","phase-4-concomitant-hpv-vaccination-and-hpv-screening-hpv-infection-and-cervical-cancer-in-sweden-100432414",false,"NCT04910802","Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden","Concomitant HPV Vaccination and HPV Screening for Rapid Elimination of HPV Infection and Cervical Cancer in Sweden","Inclusion Criteria:\n\n* Eligible women will include resident women within the age range of 22-26, who have not opted out of the screening program and who consent to participate in the study.\n\nWomen who respond to the invitation and attend screening will be screened with HPV testing by the current routine practise. Women who consent to participate will also be offered HPV vaccination. The HPV vaccine (Gardasil 9) will be offered regardless of whether the woman reports having had prior vaccination with a first-generation vaccine (Gardasil 4) and regardless of screening test result.\n\nExclusion Criteria:\n\n1. Known history of severe allergic reaction or hypersensitivity to any of the components of the HPV vaccine.For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate\n2. Known history of immune-related disorders\n3. Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever.\n4. Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose\n5. Current pregnancy (reported)\n6. Women with a total hysterectomy","FEMALE","22 Years","27 Years",{"count":74,"type":75},150000,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.",[81,82,83],"HPV Infection","CIN 2\u002F3","Cervical Cancer","2021-09-09",{"date":86,"type":87},"2021-09-16","ACTUAL",{"date":89,"type":87},"2021-05-03",{"date":91,"type":75},"2027-12-31",{"name":57,"class":6},1]